1-10 of 10
Sylvain Baruchel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report

Sarah E.S. Leary, Julie R. Park, Joel M. Reid, Andrew T. Ralya, Sylvain Baruchel, Bing Wu, Timothy P.L. Roberts, Xiaowei Liu, Charles G. Minard, Elizabeth Fox, Brenda Weigel, Susan Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6062–6069.
https://doi.org/10.1158/1078-0432.CCR-16-2882
Published: 12 October 2017
View article titled, Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report
Open the PDF for Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report in another window
Journal Articles

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models

Libo Zhang, Paula Marrano, Bing Wu, Sushil Kumar, Paul Thorner, Sylvain Baruchel
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2697–2708.
https://doi.org/10.1158/1078-0432.CCR-15-1853
Published: 31 May 2016
View article titled, Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Open the PDF for Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors

Libo Zhang, Paula Marrano, Sushil Kumar, Michael Leadley, Evelyn Elias, Paul Thorner, Sylvain Baruchel
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (21): 5972–5983.
https://doi.org/10.1158/1078-0432.CCR-13-1485
Published: 31 October 2013
View article titled, Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
Open the PDF for Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6011–6022.
https://doi.org/10.1158/1078-0432.CCR-11-3284
Published: 06 November 2012
View article titled, A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Julia Glade Bender, Susan M. Blaney, Scott Borinstein, Joel M. Reid, Sylvain Baruchel, Charlotte Ahern, Ashish M. Ingle, Darrell J. Yamashiro, Alice Chen, Brenda Weigel, Peter C. Adamson, Julie R. Park
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 5081–5089.
https://doi.org/10.1158/1078-0432.CCR-12-0078
Published: 16 September 2012
View article titled, A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

Sushil Kumar, Reza Bayat Mokhtari, Reihaneh Sheikh, Bing Wu, Libo Zhang, Ping Xu, Shan Man, Indhira Dias Oliveira, Herman Yeger, Robert S. Kerbel, Sylvain Baruchel
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5656–5667.
https://doi.org/10.1158/1078-0432.CCR-11-0078
Published: 01 September 2011
View article titled, Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
Open the PDF for Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor in another window
Journal Articles

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

Steven G. DuBois, Suzanne Shusterman, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Bing Wu, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Holcombe E. Grier, Peter C. Adamson, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5113–5122.
https://doi.org/10.1158/1078-0432.CCR-11-0237
Published: 31 July 2011
View article titled, Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study in another window
Journal Articles

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

Rena Buckstein, Robert S. Kerbel, Yuval Shaked, Rakesh Nayar, Cindy Foden, Ruth Turner, Christine R. Lee, Diane Taylor, Liying Zhang, Shan Man, Sylvain Baruchel, Diana Stempak, Francesco Bertolini, Michael Crump
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5190–5198.
https://doi.org/10.1158/1078-0432.CCR-06-0474
Published: 01 September 2006
View article titled, High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
Open the PDF for High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study

Loretta Lau, Jeffery G. Supko, Susan Blaney, Linda Hershon, Nita Seibel, Mark Krailo, Wenchun Qu, David Malkin, Jose Jimeno, Mark Bernstein, Sylvain Baruchel, for the Children's Oncology Group
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (2): 672–677.
https://doi.org/10.1158/1078-0432.672.11.2
Published: 08 February 2005
View article titled, A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study
Open the PDF for A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study in another window
Journal Articles

Targeting Cyclooxygenase-2 Reduces Overt Toxicity toward Low-Dose Vinblastine and Extends Survival of Juvenile Mice with Friend Disease

Dave Cervi, Giannoula Klement, Diana Stempak, Sylvain Baruchel, Alane Koki, Yaacov Ben-David
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (2): 712–719.
https://doi.org/10.1158/1078-0432.712.11.2
Published: 08 February 2005
View article titled, Targeting Cyclooxygenase-2 Reduces Overt Toxicity toward Low-Dose Vinblastine and Extends Survival of Juvenile Mice with Friend Disease
Open the PDF for Targeting Cyclooxygenase-2 Reduces Overt Toxicity toward Low-Dose Vinblastine and Extends Survival of Juvenile Mice with Friend Disease in another window